Skip to main content

Table 2 Malignant lesions: location, FDG-SUVpeak, FLT-SUVpeak, ADCmedian, and outcome

From: 18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study

Pt no

Lesion no

Location

FDG-PET

FLT-PET

DW-MRI

Lesion outcome

Comments

SUVpeak

SUVpeak

ADCmedian

Lesion response

Progression (days)

 

1

1-T

LLL

16.5

1.6

1.22

Response

–

 

1-N1

2R + 4R

12.2

1.8

1.21

Response

–

 

1-N2

10L + 11L

13.4

1.5

0.90

Response

–

 

1-N3

4L

15.5

1.9

0.88

Response

–

 

1-N4

7

17.3

2.1

1.07

Response

  

1-M

RUL

4.2

1.1

1.05

Response

–

 

2

2-N

2R + 4R + 4L + 7

NA

1.3

1.54

Response

194

 

3

3-T

LLL + hilus sin

9.0

2.1

1.59

Response

–

 

3-N1

8

8.1

1.6

1.96

Response

–

 

3-N2

7

5.5

1.2

1.89

Response

–

 

3-N3

4L + 4R + 5

8.0

1.3

1.39

Response

134

 

4

4-T

LUL

22.7

11.5

1.43

No change

90

 

5

5-T

Hilus dxt

NA

2.6

1.74

No change

–

Previously irradiated

6

6-T

RLL

3.9

0.6

#

Response

155

 

6-N

10-11R

6.2

1.3

2.09

Response

–

 

7

7-T

LUL + hilus + med

8.3

4.0

NA

NA

NA

No outcome evaluation as the patient died day 47

7-M

Lymph node in left axilla

5.2

1.9

NA

NA

NA

No outcome evaluation as the patient died day 47

8

8-T1

RUL + med

9.7

1.7

1.11

Response

–

 

8-T2

RUL

2.0

0.6

#

Response

–

 

8-T3

RUL

2.2

0.7

#

Response

–

 

9

9-T1

LUL + med

12.1

1.7

1.74

Response

195

 

9-T2

LUL

3.7

1.3

1.01

Response

–

 

10

10-T1

hilus sin + med

NA

2.8

0.82

Response

124

Previously irradiated

10-T2

lingula

NA

1.9

1.10

Response

–

 

11

11-T1

RUL + med

11.8

3.0

1.15

No change

275

 

11-T2

RUL

4.4

1.0

0.76

NA

–

Response evaluation not possible due to atelectasis

11-M1

Subcutis + os frontale

8.9

2.3

1.03

No change

–

 

11-M2

Subcutis + costa

10.9

4.6

1.03

No change

–

 

12

12-T

RUL

12.8

1.2

1.19

Response

–

 

12-N1

4 + 7

11.6

2.4

1.56

Progression

50

 

12-N2

7 + 8

10.2

2.2

1.85

Progression

50

 

12-N3

10-11R

13.7

1.9

1.61

Progression

50

 
  1. LLL left lower lobe, RUL right upper lobe, 2R, 4R, etc lymph node stations, LUL left upper lobe, RLL right lower lobe; med: mediastinum, FDG 18F-fluorodeoxy-glucose, PET positron emission tomography, SUV standardized uptake value, FLT 18F-fluorothymidine, DW diffusion weighted, MRI magnetic resonance imaging, ADC apparent diffusion coefficient, NA not available, # Tumor not visible on MRI and/or DW-MRI